Effect of tamoxifen on the pharmacokinetics of theophylline in rats

Journal of Pharmacy and Pharmacology

Volumn 49, Issue 1, 1997, Pages 40-42

  Poisson, Denise ^a   Dupuis, Antoine ^b   Breteau, Michel ^a   Bouquet, Serge ^b   Poterre, Marc ^c   Couet, William ^b,d  

^a UNIVERSITÉ DE TOURS   (France)

^b UPRES EA 1223   (France)

^c Zeneca Pharma   (France)

^d Faculte de Medicine et de Pharmacie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN CITRATE; THEOPHYLLINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN RESIDENCE TIME; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RISK;

EID: 0031032479     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1997.tb06749.x     Document Type: Article

References (30)

1. Adam, H. K. (1981) A review of the pharmacokinetics and metabolism of Nolvadex (tamoxifen). In: Sutherland, R. L., Jordan, V. C. (eds) Non Steroidal Antioestrogens. Academic Press, Sydney, pp 59-74
2. Arimori, K., Nalcano, M. (1988) Dose-dependency in the exsorption of theophylline and the intestinal dialysis of theophylline by oral activated charcoal in rats. J. Pharm. Pharmacol. 40: 101-105
3. Borgna, J. L., Rochefort, H. (1981) Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissue. J. Biol. Chem. 256: 859
4. th European Congress of Biopharmaceutics and Pharmacokinetics proceedings. Eur. J. Drug Metab. Pharmacokinet., special issue, pp 56-57
5. Buckley, M. M., Goa, K. L. (1989) Tamoxifen, a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 37: 451-490
6. Busby, M., Lesko, L. J. (1987) Pharmacokinetic interaction between theophylline and chloramphenicol in rats. Drug Metab. Dispos. 15: 204-206
7. Camaggi, C. M., Stocci, E., Canova, N., Panutti, F. (1983) High performance liquid chromatographic analysis of tamoxifen and major metabolites in human plasma. J. Chromatogr. 275: 436-442
8. Fromson, J. H., Pearson, S., Bramah, S. (1973a) The metabolism of tamoxifen (ICI 46,474). Part I. In laboratory animals. Xenobiotica 3: 693-709
9. Fromson, J. H., Pearson, S., Bramah, S. (1973b) The metabolism of tamoxifen (ICI 46,474). Part II. In female patients. Xenobiotica 3: 711-714
10. Gibaldi, M., Perrier, D. (1982) Pharmacokinetics, 2nd edn. Marcel Dekker Inc., New York
11. Gustovic, P., Baldin, B., Tricoire, M. J., Chichmanian, R. M. (1994) Interaction tamoxifene-acénocoumarol, une interaction potentiellement dangereuse. Thérapie 49: 55-56
12. Lien, E., Anker, G., Lonning, P. E., Solheim, E., Ueland, P. M. (1990) Decreased serum concentration of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 50: 5851-5887
13. Lodwick, R., McConkey, B., Brown, A. M. (1987) Life threatening interaction between tamoxifen and warfarin. Br. Med. J. 295: 1141
14. Mani, C., Gelboin, H. V., Park, S. S., Pearce, R., Parkinson, A., Kupfer, D. (1993a) Metabolism of the antimammary cancer antiestrogenic agent tamoxifen I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21: 645-656
15. Mani, C., Hodgson, E., Kupfer, D. (1993b) Metabolism of the antimammary cancer antiestrogenic agent tamoxifen II. Flavin-containing monooxygenase-mediated N-oxidation. Drug Metab. Dispos. 21: 657-661
16. Meltzer, N. M., Stang, P., Sternson, L. A. (1984) Influence of tamoxifen and its N-desmethyl and 4-hydroxy metabolites on rat liver microsomal enzymes. Biochem. Pharmacol. 33: 115-123
17. Nayfield, S., Karp, J., Ford, L., Dorr, F., Kramer, B. (1991) Potential role of tamoxifen in prevention of breast cancer. J. Natl Cancer Inst. 83: 1450-1459
18. Nuwaysir, E. F., Dragan Y. P., Jefcoate C. R., Jordan V. C., Pitot H. C. (1995) Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver. Cancer Res. 55: 1780-1786
19. Powles, T. J., Jones, A. L., Ashley, S. E., O'Brien, M. E. R., Tidy, V. A., Treleavan, J., Cosgrove, D., Nash, A. G., Sacks, N., Baum, M., McKinna, J. A., Davey, J. B. (1994) The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res. Treat. 31: 73-82
20. Prentice. R. (1990) Tamoxifen as a potential preventive agent in healthy postmenopausal women. J. Natl Cancer Inst. 82: 12-13
21. Reid, A. D., Horobin, J. M., Newman, E. L., Preece, P. E. (1992) Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients. Breast Cancer Res. Treat. 22: 153-156
22. Ritchie, L. D., Grant, S. M. T. (1989) Tamoxifen-warfarin interaction: Aberdeen hospital drugs files. Br. Med. J. 298: 1253
23. Robinson, S. P., Langan-Fahey, S. M., Johnson, D. A., Jordan, V. C. (1991) Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab. Dispos. 19: 36-43
24. Tang Liu, D. D. S., Williams, R. L., Riegelman, S. (1982) Non-linear theophylline elimination. Clin. Pharmacol. Ther. 31: 358-369
25. Tenni, P., Lalich, D. L., Byrne, M. J. (1989) Life threatening interaction between tamoxifen and warfarin. Br. Med. J. 298: 93
26. Teunissen, M. W. E., Brorens, I. O. N., Geerlings, J. M., Breimer, D. D. (1985) Dose-dependent elimination of theophylline in rats. Xenobiotica 2: 165-171
27. Tucker, G. T. (1992) The rational selection of drug interaction studies: implication of recent advances in drug metabolism. Int. J. Clin. Pharmacol. Ther. Toxicol. 11: 550-553
28. Upton, R. (1991a) Pharmacokinetic interactions between theophylline and other medication (part I). Clin. Pharmacokinet. 20: 66-80
29. Upton, R. (1991b) Pharmacokinetic interactions between theophylline and other medication (part II). Clin. Pharmacokinet. 20: 135-150
30. Zeruersenay, D., Siegmung, W., Zschiesche, M., Franke, G., Walter, R., Bleyer, H. (1992) Pharmacokinetic interactions between isoniazid and theophylline in rats. J. Pharm. Pharmacol. 44: 893-897